𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gemcitabine and platinum combinations in pancreatic cancer

✍ Scribed by Philip Agop Philip

Book ID
102103804
Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
62 KB
Volume
95
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Progress in the treatment of pancreatic cancer in the past several decades has been very modest. Several new agents with activity against this disease have been identified. Of these, gemcitabine appears to be the most promising when used in combination with other drugs. Gemcitabine and cisplatin combinations have been tested in several studies. The major toxicity reported to occur with the gemcitabine-cisplatin combination is myelosuppression, which is greater than that encountered with single-agent gemcitabine. However, episodes of neutropenic fever or spontaneous bleeding are reported to be very infrequent. Pilot Phase II studies combining gemcitabine with cisplatin have shown improved outcomes in objective response rates and survival; however, these findings must be confirmed in larger randomized studies.

πŸ“œ SIMILAR VOLUMES

The pemetrexed/gemcitabine combination i
The pemetrexed/gemcitabine combination in pancreatic cancer
✍ Hedy Lee Kindler πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 89 KB

Gemcitabine has modest antitumor activity in advanced pancreatic cancer. New agents are clearly needed. Pemetrexed (ALIMTA) is a novel antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has shown in vitro activity agai

Combined gemcitabine and radioimmunother
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
✍ Thomas M. Cardillo; Rosalyn Blumenthal; Zhiliang Ying; David V. Gold πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 116 KB πŸ‘ 1 views

## Abstract MAb‐PAM4 is an anti‐MUC1 antibody that has been shown to be reactive with 85% of pancreatic adenocarcinomas with no reactivity with normal pancreas or other tissues. Initial clinical studies have shown excellent targeting with high tumor/nontumor ratios. Gemcitabine, an analog of deoxyc

Gemcitabine-based therapy in pancreas ca
Gemcitabine-based therapy in pancreas cancer : Gemcitabine-docetaxel and other novel combinations
✍ Andrew D. Jacobs πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 69 KB

Since its approval in 1998 by the Food and Drug Administration, gemcitabine has rapidly become accepted as a standard part of palliative therapy for patients with advanced pancreatic cancer. It has modest activity when used as a single agent, and this has led to numerous studies combining it with ot